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In patients with heart failure (HF) treated with loop diuretics, RAAS inhibition and digoxin, volume overload is a sign of decompensation and often 
heralds acute HF. The β-Blocker Evaluation of Survival Trial (BEST) evaluated the effects of bucindolol vs. placebo in advanced HF. Volume status 
at baseline (BL) was not an exclusion criterion. JVD, edema > pedal, rales 1/2 way up, and hepatomegaly at BL were used to categorize volume 
overload (VOL) or euvolemia (EUV). LVEF at BL was measured by radionuclide techniques.
Results: presented below. All-cause mortality [hazard ratio (HR) and events/patients at-risk (%) by volume status and LVEF at BL. 
Patient Group Placebo (%) Bucindolol (%) HR (95% CI)
All Pts 439/1354 (32) 402/1354 (30) 0.87 (0.76, 1.00)
EUV 252/862 (29) 208/870 (24) 0.74 (0.61,0.89)
VOL 187/492 (38)# 194/484 (40)# 1.10 (0.89,1.34)*
EF ≥0.25 161/610 (26) 130/566 (23) 0.82 (0.65,1.04)
EF <0.25 278/744 (37)# 272/788 (35)# 0.88 (0.75,1.05)
EUV, EF ≥0.25 89/396 (22) 78/394 (20) 0.83 (0.61,1.13)
EUV, EF <0.25 163/466 (35)# 130/476 (27)# 0.69 (0.55,0.88)
VOL, EF ≥0.25 72/214 (34) 52/172 (30) 0.87 (0.60,1.24)
VOL, EF <0.25 115/278 (41) 142/312 (46)# 1.15 (0.89,1.49) 
# p <0.01 for covariate subgroup comparison w/in treatment group;
* p <0.01 for treatment by covariate grouping interaction.
At BL 36% of pts had VOL and 57% had EF <0.25. Presence of both VOL and EF <0.25 was associated with highest mortality and the effect was 
additive; in placebo pts, mortality increased by 30% in VOL, 42% in EF <0.25 and 86% in VOL + EF <0.25 vs EUV + EF ≥0.25. As single variables VOL 
but not EF <0.25, prevented the beneficial effect of bucindolol on mortality (interaction p <0.01). The effect of bucindolol on mortality in pts with EF 
<0.25 depended on volume status, with trends for worsened outcomes in VOL and better outcomes in EUV.
Conclusions:  These data suggest that use of bucindolol, and potentially other β-blockers, may be associated with a greater mortality benefit in 
patients with EF <0.25 and EUV. β-blockers should be used with caution in pts with VOL and EF <0.25.
